Phase 3 study of the efficacy, pharmacokinetics, immunogenicity and safety of von
Willebrand Factor/Factor VIII concentrate in patients with severe von Willebrand Disease
under 6 years of age
Authors
A Jain
1
Loma Linda University School of Medicine, Loma Linda, USA
T-E Weisz
2
Octapharma Pharmazeutika Produktionsges.m.b.H, Vienna, Austria
